Shots:
- The CHMP has recommended Celltrion‘s Steqeyma autoinjector (45mg/0.5mL & 90mg/1mL), a biosimilar version of Stelara (ustekinumab), for the treatment of pts with plaque psoriasis, psoriatic arthritis (PsA) & Crohn’s disease (CD)
- SteQeyma (CT-P43) is a human anti-IL-12 & IL-23 monoclonal antibody that is also available in SC formulation (45mg/0.5 mL or 90mg/1 mL in PFS & prefilled pen as well as 45mg/0.5mL in vial) & IV infusion (130mg/26mL)
- Steqeyma is licensed in 40+ countries, incl. the US, Japan & EU, with its citrate-free autoinjector presentation featuring thin-wall needle technology to reduce injection pain
Ref: PRnewswire | Image: Celltrion | Press Release
Related News: The US FDA Approves Additional Presentation of Celltrion’s Omlyclo (Biosimilar, Xolair)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
